Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Agreement between chest ultrasonography and chest X-ray in patients who have undergone thoracic surgery: preliminary results.

Smargiassi A, Inchingolo R, Chiappetta M, Ciavarella LP, Lopatriello S, Corbo GM, Margaritora S, Richeldi L.

Multidiscip Respir Med. 2019 Mar 4;14:9. doi: 10.1186/s40248-019-0171-x. eCollection 2019.

2.

New Frontiers in Ultrasonography of the Mediastinum: Pediatric EBUS-TBNA.

Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, Richeldi L.

Respir Care. 2019 Mar;64(3):358-359. doi: 10.4187/respcare.06831. No abstract available.

PMID:
30850556
3.

Educational interventions alone and combined with port protector reduce the rate of central venous catheter infection and colonization in respiratory semi-intensive care unit.

Inchingolo R, Pasciuto G, Magnini D, Cavalletti M, Scoppettuolo G, Montemurro G, Smargiassi A, Torelli R, Sanguinetti M, Spanu T, Corbo GM, Richeldi L.

BMC Infect Dis. 2019 Mar 4;19(1):215. doi: 10.1186/s12879-019-3848-z.

4.

Subclinical Interstitial Lung Abnormalities; Lumping and Splitting Revisited.

Walsh SLF, Richeldi L.

Am J Respir Crit Care Med. 2019 Jan 30. doi: 10.1164/rccm.201901-0180ED. [Epub ahead of print] No abstract available.

PMID:
30699307
5.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

PMID:
30665517
6.

Quantitative analysis of lung sounds for monitoring idiopathic pulmonary fibrosis: a prospective pilot study.

Sgalla G, Larici AR, Sverzellati N, Bartholmai B, Walsh SLF, Nikolic D, Barney A, Fletcher S, Jones M, Davies DD, Richeldi L.

Eur Respir J. 2019 Mar 7;53(3). pii: 1802093. doi: 10.1183/13993003.02093-2018. Print 2019 Mar. No abstract available.

PMID:
30578384
7.

Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.

Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G.

Eur Respir Rev. 2018 Dec 21;27(150). pii: 180074. doi: 10.1183/16000617.0074-2018. Print 2018 Dec 31. Review.

8.

Reply to Moodley and to Ravaglia et al.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Wilson K.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):667-669. doi: 10.1164/rccm.201810-2006LE. No abstract available.

PMID:
30566844
9.

Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.

Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML, Esperet CA, Soubrane C.

Chest. 2018 Dec;154(6):1359-1370. doi: 10.1016/j.chest.2018.08.1083.

PMID:
30526970
10.

Existing and emerging biomarkers for disease progression in idiopathic pulmonary fibrosis.

Inchingolo R, Varone F, Sgalla G, Richeldi L.

Expert Rev Respir Med. 2019 Jan;13(1):39-51. doi: 10.1080/17476348.2019.1553620. Epub 2018 Dec 17.

PMID:
30526140
11.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
12.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

13.

Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement.

Gramegna A, Aliberti S, Confalonieri M, Corsico A, Richeldi L, Vancheri C, Blasi F.

Multidiscip Respir Med. 2018 Oct 8;13:39. doi: 10.1186/s40248-018-0153-4. eCollection 2018.

14.

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).

Raghu G, Richeldi L, Crestani B, Wung P, Bejuit R, Esperet C, Antoni C, Soubrane C.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801130. doi: 10.1183/13993003.01130-2018. Print 2018 Dec.

PMID:
30337444
15.

Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations.

Magnini D, Fuso L, Varone F, D'Argento E, Martini M, Pecoriello A, Di Noia V, Arciuolo D, Fadda G, Rindi G, Richeldi L.

Mol Diagn Ther. 2018 Dec;22(6):723-728. doi: 10.1007/s40291-018-0359-3.

PMID:
30276554
16.

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.

Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, Quaresma M, Stowasser S, Martinez FJ; INSTAGE Investigators.

N Engl J Med. 2018 Nov 1;379(18):1722-1731. doi: 10.1056/NEJMoa1811737. Epub 2018 Sep 15.

PMID:
30220235
17.

Diagnosing idiopathic pulmonary fibrosis in 2018: bridging recommendations made by experts serving different societies.

Richeldi L, Wilson KC, Raghu G.

Eur Respir J. 2018 Sep 6;52(3). pii: 1801485. doi: 10.1183/13993003.01485-2018. Print 2018 Sep. No abstract available.

PMID:
30190265
18.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
19.

Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis.

Graziani F, Varone F, Crea F, Richeldi L.

Eur J Heart Fail. 2018 Oct;20(10):1385-1391. doi: 10.1002/ejhf.1286. Epub 2018 Aug 7. Review.

PMID:
30085383
20.

Ultrasonography of the Mediastinum: Techniques, Current Practice, and Future Directions.

Fuso L, Varone F, Magnini D, Calvello M, Lo Greco E, Richeldi L.

Respir Care. 2018 Nov;63(11):1421-1438. doi: 10.4187/respcare.06047. Epub 2018 Jul 31. Review.

PMID:
30065076
21.

Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis.

Yao L, Conforti F, Hill C, Bell J, Drawater L, Li J, Liu D, Xiong H, Alzetani A, Chee SJ, Marshall BG, Fletcher SV, Hancock D, Coldwell M, Yuan X, Ottensmeier CH, Downward J, Collins JE, Ewing RM, Richeldi L, Skipp P, Jones MG, Davies DE, Wang Y.

Cell Death Differ. 2018 Jul 26. doi: 10.1038/s41418-018-0175-7. [Epub ahead of print]

22.

Reply to Rajchgot et al.: Combination Nintedanib and Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis.

Vancheri C, Kreuter M, Richeldi L, Quaresma M, Stowasser S, Wuyts WA.

Am J Respir Crit Care Med. 2018 Oct 15;198(8):1105-1106. doi: 10.1164/rccm.201806-1116LE. No abstract available.

PMID:
30025211
23.

Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.

Wu X, Kim GH, Salisbury ML, Barber D, Bartholmai BJ, Brown KK, Conoscenti CS, De Backer J, Flaherty KR, Gruden JF, Hoffman EA, Humphries SM, Jacob J, Maher TM, Raghu G, Richeldi L, Ross BD, Schlenker-Herceg R, Sverzellati N, Wells AU, Martinez FJ, Lynch DA, Goldin J, Walsh SLF.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):12-21. doi: 10.1164/rccm.201803-0444PP. No abstract available.

24.

Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis.

Jones MG, Andriotis OG, Roberts JJ, Lunn K, Tear VJ, Cao L, Ask K, Smart DE, Bonfanti A, Johnson P, Alzetani A, Conforti F, Doherty R, Lai CY, Johnson B, Bourdakos KN, Fletcher SV, Marshall BG, Jogai S, Brereton CJ, Chee SJ, Ottensmeier CH, Sime P, Gauldie J, Kolb M, Mahajan S, Fabre A, Bhaskar A, Jarolimek W, Richeldi L, O'Reilly KM, Monk PD, Thurner PJ, Davies DE.

Elife. 2018 Jul 3;7. pii: e36354. doi: 10.7554/eLife.36354.

25.

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.

Flaherty KR, Kolb M, Vancheri C, Tang W, Conoscenti CS, Richeldi L.

Eur Respir J. 2018 Aug 2;52(2). pii: 1702593. doi: 10.1183/13993003.02593-2017. Print 2018 Aug.

PMID:
29946007
26.

"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease.

Sgalla G, Walsh SLF, Sverzellati N, Fletcher S, Cerri S, Dimitrov B, Nikolic D, Barney A, Pancaldi F, Larcher L, Luppi F, Jones MG, Davies D, Richeldi L.

BMC Pulm Med. 2018 Jun 18;18(1):103. doi: 10.1186/s12890-018-0670-0.

27.

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L.

JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.

28.

Optimising experimental research in respiratory diseases: an ERS statement.

Bonniaud P, Fabre A, Frossard N, Guignabert C, Inman M, Kuebler WM, Maes T, Shi W, Stampfli M, Uhlig S, White E, Witzenrath M, Bellaye PS, Crestani B, Eickelberg O, Fehrenbach H, Guenther A, Jenkins G, Joos G, Magnan A, Maitre B, Maus UA, Reinhold P, Vernooy JHJ, Richeldi L, Kolb M.

Eur Respir J. 2018 May 17;51(5). pii: 1702133. doi: 10.1183/13993003.02133-2017. Print 2018 May.

PMID:
29773606
29.

Idiopathic pulmonary fibrosis: pathogenesis and management.

Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L.

Respir Res. 2018 Feb 22;19(1):32. doi: 10.1186/s12931-018-0730-2. Review.

30.

Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis.

Kreuter M, Costabel U, Richeldi L, Cottin V, Wijsenbeek M, Bonella F, Bendstrup E, Maher TM, Wachtlin D, Stowasser S, Kolb M.

Respiration. 2018;95(5):317-326. doi: 10.1159/000486286. Epub 2018 Feb 7.

31.

Diagnostic criteria for idiopathic pulmonary fibrosis - Authors' reply.

Lynch DA, Sverzellati N, Travis WD, Colby TV, Inoue Y, Nicholson AG, Raoof S, Richeldi L, Ryerson CJ, Ryu JH.

Lancet Respir Med. 2018 Feb;6(2):e7. doi: 10.1016/S2213-2600(18)30021-3. No abstract available.

PMID:
29413090
32.

Validation of multidisciplinary diagnosis in IPF.

Castillo D, Walsh S, Hansell DM, Vasakova M, Cottin V, Altinisik G, Palmucci S, Sterclova M, Harari S, Richeldi L, Vancheri C, Wells AU; ERICE ILD working group.

Lancet Respir Med. 2018 Feb;6(2):88-89. doi: 10.1016/S2213-2600(18)30023-7. Review. No abstract available.

PMID:
29413085
33.

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Wolters PJ, Blackwell TS, Eickelberg O, Loyd JE, Kaminski N, Jenkins G, Maher TM, Molina-Molina M, Noble PW, Raghu G, Richeldi L, Schwarz MI, Selman M, Wuyts WA, Schwartz DA.

Lancet Respir Med. 2018 Feb;6(2):154-160. doi: 10.1016/S2213-2600(18)30007-9. Review.

34.

Nintedanib for the treatment of idiopathic pulmonary fibrosis.

Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L.

Expert Opin Pharmacother. 2018 Feb;19(2):167-175. doi: 10.1080/14656566.2018.1425681. Epub 2018 Jan 12. Review.

PMID:
29327616
35.

Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.

Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU.

Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Review.

36.

COPD management as a model for all chronic respiratory conditions: report of the 4th Consensus Conference in Respiratory Medicine.

Nardini S, De Benedetto F, Sanguinetti CM, Bellofiore S, Carlone S, Privitera S, Sagliocca L, Tupputi E; with the collaboration of The Consensus Conference Group, Baccarani C, Caiffa G, Calabrese MC, Capuozzo A, Cauchi S, Conio V, Coratella G, Crismancich F, Dal Negro RW, Dellarole F, Delucchi M, Favaretti C, Forte S, Gallo FM, Giuliano R, Grandi M, Grillo A, Gualano MR, Guffanti E, Locicero S, Lombardo FP, Mantero M, Marasso R, Martino L, Mastroberardino M, Mereu C, Messina R, Neri M, Novelletto BF, Parente P, Pasquinucci S, Pistolesi M, Polverino M, Posca A, Richeldi L, Roccia F, Giustini ES, Salemi M, Santacroce S, Schisano M, Schisano M, Selvi E, Silenzi A, Soverina P, Taranto C, Ugolini M, Visaggi P, Zanasi A.

Multidiscip Respir Med. 2017 Nov 10;12:28. doi: 10.1186/s40248-017-0109-0. eCollection 2017.

37.

Idiopathic pulmonary fibrosis.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU.

Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Review.

PMID:
29052582
38.

Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease.

Flaherty KR, Brown KK, Wells AU, Clerisme-Beaty E, Collard HR, Cottin V, Devaraj A, Inoue Y, Le Maulf F, Richeldi L, Schmidt H, Walsh S, Mezzanotte W, Schlenker-Herceg R.

BMJ Open Respir Res. 2017 Sep 17;4(1):e000212. doi: 10.1136/bmjresp-2017-000212. eCollection 2017.

39.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

40.

Managing patients with interstitial lung disease: Two more pieces of the puzzle.

Macagno F, Leone PM, Richeldi L.

Respirology. 2017 Nov;22(8):1481-1482. doi: 10.1111/resp.13195. Epub 2017 Oct 4. No abstract available.

41.

Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?

Inchingolo R, Condoluci C, Smargiassi A, Mastrobattista A, Boccabella C, Comes A, Golfi N, Richeldi L.

Expert Opin Pharmacother. 2017 Oct;18(15):1583-1594. doi: 10.1080/14656566.2017.1383382. Epub 2017 Sep 27. Review.

PMID:
28933616
42.

Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis.

Sgalla G, Richeldi L.

Rev Port Pneumol (2006). 2017 Sep - Oct;23(5):245-246. doi: 10.1016/j.rppnen.2017.08.005. No abstract available.

43.

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.

Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC.

PMID:
28889759
44.

Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.

Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium.

Eur Respir J. 2017 Aug 31;50(2). pii: 1700936. doi: 10.1183/13993003.00936-2017. Print 2017 Aug.

45.

Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis.

Jones MG, Sgalla G, Richeldi L.

Am J Respir Crit Care Med. 2018 Jan 1;197(1):9-10. doi: 10.1164/rccm.201708-1666ED. No abstract available.

PMID:
28841036
46.

Investigational drugs for idiopathic pulmonary fibrosis.

Varone F, Montemurro G, Macagno F, Calvello M, Conte E, Intini E, Iovene B, Leone PM, Mari PV, Richeldi L.

Expert Opin Investig Drugs. 2017 Sep;26(9):1019-1031. doi: 10.1080/13543784.2017.1364361. Epub 2017 Aug 10. Review.

PMID:
28777013
47.

Current approaches to the management of idiopathic pulmonary fibrosis.

Raghu G, Richeldi L.

Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017. Epub 2017 May 30. Review.

PMID:
28732832
48.

Individualizing duration of antibiotic therapy in community-acquired pneumonia.

Aliberti S, Ramirez J, Giuliani F, Wiemken T, Sotgiu G, Tedeschi S, Carugati M, Valenti V, Marchioni M, Camera M, Piro R, Del Forno M, Milani G, Faverio P, Richeldi L, Deotto M, Villani M, Voza A, Tobaldini E, Bernardi M, Bellone A, Bassetti M, Blasi F.

Pulm Pharmacol Ther. 2017 Aug;45:191-201. doi: 10.1016/j.pupt.2017.06.008. Epub 2017 Jun 27.

PMID:
28666965
49.

Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Johannson KA, Strâmbu I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, Luppi F, Richeldi L, Wells AU, Vancheri C, Kreuter M; Erice ILD Working Group.

Lancet Respir Med. 2017 Jul;5(7):591-598. doi: 10.1016/S2213-2600(17)30219-9. Review.

PMID:
28664861
50.

New treatment directions for IPF: current status of ongoing and upcoming clinical trials.

Macagno F, Varone F, Leone PM, Mari PV, Panico L, Berardini L, Richeldi L.

Expert Rev Respir Med. 2017 Jul;11(7):533-548. doi: 10.1080/17476348.2017.1335601. Epub 2017 May 31.

PMID:
28544857

Supplemental Content

Loading ...
Support Center